HER2-specific T cells As An Immunotherapy In HER2-Positive Sarcoma (2015)
http://immuno-oncologynews.com/2015/...itive-sarcoma/
Dr. Gottschalk explained that T cells have been used as a cancer immunotherapy over the last 10 to 15 years, but there not been many CAR T-cell therapy studies for solid tumors have been developed so far, mainly for those expressing the HER2 protein. Dr. Gottschalk added that HER2-CAR T cells are safe in high doses, and because HER2 is expressed in a wide variety of tumors, this strategy can be applied to many patients. Dr. Gottschalk added that “If you look at the history of cancer therapy, there are few examples of ‘magic bullets’ that can cure cancer alone.” As such, combining HER2-CAR T cells with other types of cancer therapeutics can prove efficient in the future of cancer research.